Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma

The purpose of this study is to assess the safety, tolerability, drug levels, and preliminary
efficacy of relatlimab plus nivolumab in pediatric and young adult participants with
recurrent or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Lymphoma, Pediatrics
Phase I/II
Both
Mol. targeted/Immunotherapy/Biologics
Nivolumab, Relatlimab
Friedman, Debra
International
Vanderbilt University
09-06-2022
Supportive Care
VICCPEDP21106
NCT05255601

Eligibility

0 Years
BOTH
NO
Inclusion Criteria:

Pathologically confirmed high-risk recurrent/relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL), after non-response to or failure of first-line standard therapy prior to a definitive therapy e.g.high-dose chemotherapy/autologous stem cell transplant (HDCT/ASCT)

Participants with pathologically confirmed R/R NHL after failure or non-response to second line therapy, including but not limited to primary mediastinal B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL), mediastinal gray zone lymphoma (MGZL), anaplastic large cell lymphoma (ALCL), or peripheral T-cell lymphoma (PTCL).

Participants must have measurable PET positive disease in both cHL and NHL cohorts.



Exclusion Criteria:

Aggressive B-cell lymphomas subtypes including Burkitt lymphoma (BL), lymphoblastic lymphoma, and NK/T-cell lymphoma/leukemia.

Primary CNS lymphoma of the brain or spinal cord, and secondary CNS lymphoma (ie, from systemic non-Hodgkin lymphoma) involving the brain, spinal cord, or with leptomeningeal seeding.

Prior treatment with an anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways, with the exception of anti-PD(L)-1 targeted therapies

Prior treatment with lymphocyte activation gene-3 (LAG-3)-targeted agents

Prior autologous stem cell transplantation (HDCT/ASCT)

History of allogeneic bone marrow transplantation.

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: